Publication:
Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases.

Simple item page
dc.contributor.authorSolana, Jose Carlos
dc.contributor.authorMoreno, Javier
dc.contributor.authorIborra, Salvador
dc.contributor.authorSoto, Manuel
dc.contributor.authorRequena, Jose M
dc.date.accessioned2026-01-12T13:26:43Z
dc.date.available2026-01-12T13:26:43Z
dc.date.issued2022-04
dc.description.abstractThe control of diseases caused by protozoan parasites is one of the United Nations' Sustainable Development Goals. In recent years much research effort has gone into developing a new generation of live attenuated vaccines (LAVs) against malaria, Chagas disease and leishmaniasis. However, there is a bottleneck related to their biosafety, production, and distribution that slows downs further development. The success of irradiated or genetically attenuated sporozoites against malaria, added to the first LAV against leishmaniasis to be evaluated in clinical trials, is indicative that the drawbacks of LAVs are gradually being overcome. However, whether persistence of LAVs is a prerequisite for sustained long-term immunity remains to be clarified, and the procedures necessary for clinical evaluation of vaccine candidates need to be standardized.
dc.description.peerreviewedSí
dc.description.sponsorshipJ.C.S. holds a research contract from the Universidad Autonoma de Madrid (Ref. UAM/133). S.I. is funded by the Spanish Ministerio de Ciencia, Innovación (MICINN), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER), RTI2018-094484-B-I00, and RYC-2016-19463. Parts of the research described in this review were supported by a grant from the Instituto de Salud Carlos III (Network of Tropical Diseases Research, RD16/0027/0008), co-funded with FEDER funds, to J.M.R. and M.S.
dc.format.number4
dc.format.page316-334
dc.format.volume38
dc.identifier.citationSolana JC, Moreno J, Iborra S, Soto M, Requena JM. Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases. Trends Parasitol. 2022 Apr;38(4):316-334. doi: 10.1016/j.pt.2021.11.004. Epub 2021 Dec 9. PMID: 34896016.
dc.identifier.doi10.1016/j.pt.2021.11.004
dc.identifier.journalTrends in Parasitology
dc.identifier.pubmedID34896016
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27139
dc.language.isoeng
dc.publisherElsevier
dc.relation.publisherversionhttps://doi.org/10.1016/j.pt.2021.11.004
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.subjectChagas disease
dc.subjectAttenuated vaccines
dc.subjectGenetically modified parasites
dc.subjectLeishmaniasis
dc.subjectMalaria
dc.titleLive attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases.
dc.typereview article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublication2e690bd6-6f63-4aa1-8136-7f9b7da93062
relation.isAuthorOfPublication831dbac1-fcb6-444a-90e1-4b562eecb934
relation.isAuthorOfPublication831dbac1-fcb6-444a-90e1-4b562eecb934
relation.isAuthorOfPublication831dbac1-fcb6-444a-90e1-4b562eecb934
relation.isAuthorOfPublication.latestForDiscovery2e690bd6-6f63-4aa1-8136-7f9b7da93062
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
LiveAttenuatedVaccinesFavorable_2022.pdf
Size:
1.38 MB
Format:
Adobe Portable Document Format
Download

Collections

Centro Nacional de Microbiología (CNM)